Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

Coding of facial expressions of pain in the laboratory mouse

Langford, D. J., Bailey, A. L., Chanda, M. L., Clarke, S. E. D., Drummond, T. E., Echols, S., Glick, S., Ingrao, J. C., Klassen-Ross, T., LaCroix‐Fralish, M. L., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1455 · Cited by 1,570

Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling

Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820

Porphyrias

Puy, H., Gouya, L., & Deybach, J. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61925-5 · Cited by 727

Recommendations for the Diagnosis and Treatment of the Acute Porphyrias

Anderson, K. E., Bloomer, J. R., Bonkovsky, H. L., Kushner, J. P., Pierach, C. A., Pimstone, N. R., & Desnick, R. J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00010 · Cited by 622

High Throughput Microplate Respiratory Measurements Using Minimal Quantities Of Isolated Mitochondria

Rogers, G. W., Brand, M. D., Petrosyan, S., Ashok, D., Elorza, Á. A., Ferrick, D. A., & Murphy, A. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021746 · Cited by 482

Porphyria

Bissell, D. M., Anderson, K. E., & Bonkovsky, H. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608634 · Cited by 399

Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α

Handschin, C., Lin, J. D., Rhee, J., Peyer, A., Chin, S., Wu, P., Meyer, U., & Spiegelman, B. M. (2005) · Cell · doi:10.1016/j.cell.2005.06.040 · Cited by 392

Acute Porphyrias in the USA: Features of 108 Subjects from Porphyrias Consortium

Bonkovsky, H. L., Maddukuri, V. C., Yazıcı, C., Anderson, K. E., Bissell, D. M., Bloomer, J. R., Phillips, J. D., Naik, H., Peter, I., Baillargeon, G. M., et al. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.06.036 · Cited by 264

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127

mRNA-based therapeutics: powerful and versatile tools to combat diseases

Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852

Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs

Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 744

Lipid nanoparticles for nucleic acid delivery: Current perspectives

Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609

Phenylketonuria

van Spronsen, F. J., Blau, N., Harding, C. O., Burlina, A., Longo, N., & Bosch, A. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00267-0 · Cited by 506

The landscape of mRNA nanomedicine

Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511

The challenge and prospect of mRNA therapeutics landscape

Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417

Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery

Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.017 · Cited by 359

mRNA-based therapeutics: looking beyond COVID-19 vaccines

Parhiz, H., Atochina‐Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 303

Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation

Kim, J., Jozić, A., Lin, Y., Eygeris, Y., Bloom, E., Tan, X., Acosta, C., MacDonald, K. D., Welsher, K., & Sahay, G. (2022) · ACS Nano · doi:10.1021/acsnano.2c05647 · Cited by 292

Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives

Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229

Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications

Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 232

Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing

Zhang, X., Zhao, W., Nguyen, G. N., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc2315 · Cited by 184

Nanotechnology-based mRNA vaccines

Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177

Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates

Zhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.003 · Cited by 165

Clinical guide and update on porphyrias

Stölzel, U., Doss, M. O., & Schuppan, D. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.050 · Cited by 175

Nanomedicine-Based Approaches for mRNA Delivery

Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139

Novel vectors and approaches for gene therapy in liver diseases

Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & González‐Aseguinolaza, G. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100300 · Cited by 143

Current Status and Future Perspectives on MRNA Drug Manufacturing

Webb, C., Ip, S. Y., Bathula, N. V., Popova, P. G., Soriano, S. K. V., Ly, B.-H., Eryilmaz, B., Huu, V. A. N., Broadhead, R., Rabel, M., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00010 · Cited by 134

mRNA nanomedicine: Design and recent applications

Kubiatowicz, L. J., Mohapatra, A., Krishnan, N., Fang, R. H., & Zhang, L. (2022) · Exploration · doi:10.1002/exp.20210217 · Cited by 131

Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia

Jiang, L., Park, J.-S., Yin, L., Laureano, R., Jacquinet, E., Yang, J., Liang, S., Frassetto, A., Zhuo, J., Yan, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19156-3 · Cited by 129

Messenger RNA therapy for rare genetic metabolic diseases

Berraondo, P., Martini, P. G. V., Avila, M. A., & Fontanellas, A. (2019) · Gut · doi:10.1136/gutjnl-2019-318269 · Cited by 121

Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases

Trepotec, Z., Lichtenegger, E., Plank, C., Aneja, M. K., & Rudolph, C. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.012 · Cited by 115

Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy

DeRosa, F., Smith, L., Shen, Y., Huang, Y., Pan, J., Xie, H., Yahalom, B., & Heartlein, M. W. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.001 · Cited by 111

Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety

Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112

Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery

Xu, X., & Xia, T. (2023) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.2c00062 · Cited by 106

Loss of liver function in chronic liver disease: An identity crisis

Berasain, C., Arechederra, M., Argemí, J., Fernández-Barrena, M. G., & Avila, M. A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.001 · Cited by 99

Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach

Haghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 125

Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects

Liu, Y., Huang, Y., He, G., Guo, C., Dong, J., & Wu, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810166 · Cited by 100

Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States

Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80

A New Era for Rare Genetic Diseases: Messenger RNA Therapy

Martini, P. G. V., & Guey, L. T. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.090 · Cited by 88

Acute hepatic porphyrias: Current diagnosis & management

Anderson, K. E. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.07.002 · Cited by 87

Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia

An, D., Frassetto, A., Jacquinet, E., Eybye, M., Milano, J., DeAntonis, C., Nguyen, V., Laureano, R., Milton, J., Sabnis, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.003 · Cited by 87

Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications

Lopes, C., Cristóvão, J. S., Silvério, V., Lino, P. R., & Fonte, P. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2135502 · Cited by 88

RNA delivery biomaterials for the treatment of genetic and rare diseases

Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82

Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4 mouse model of PFIC3

Wei, G., Cao, J., Huang, P., An, P., Skelton-Badlani, D., Vaid, K. A., Zhao, S., Wang, D. Q. ‐., Zhuo, J., Yin, L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.010 · Cited by 74

tRNA therapeutics for genetic diseases

Coller, J., & Ignatova, Z. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00829-9 · Cited by 72

Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities

Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74

mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency

Cao, J., An, D., Galduroz, M., Zhuo, J., Liang, S., Eybye, M., Frassetto, A., Kuroda, E., Funahashi, A., Santana, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.017 · Cited by 70

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

Cao, J.-S., Choi, M., Guadagnin, E., Soty, M., Silva, M., Verzieux, V., Weisser, E., Markel, A., Zhuo, J., Liang, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23318-2 · Cited by 58

mRNA therapies: Pioneering a new era in rare genetic disease treatment

Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 62

Therapeutic mRNA delivery to leukocytes

Granot-Matok, Y., Kon, E., Dammes, N., Mechtinger, G., & Peer, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.032 · Cited by 64

Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia

Balakrishnan, B., An, D., Nguyen, V., DeAntonis, C. M., Martini, P. G. V., & Lai, K. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.018 · Cited by 57

Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency

Karadagi, A., Cavedon, A. G., Zemack, H., Nowak, G., Eybye, M. E., Zhu, X., Guadagnin, E., White, R. A., Rice, L. M., Frassetto, A. L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64017-0 · Cited by 54

Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy

Firdessa-Fite, R., & Creusot, R. J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.015 · Cited by 53

Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives

Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 60

Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators

Beyersdorf, J. P., Bawage, S. S., Iglesias, N., Peck, H. E., Hobbs, R. A., Wroe, J. A., Zurla, C., Gersbach, C. A., & Santangelo, P. J. (2022) · ACS Nano · doi:10.1021/acsnano.1c10631 · Cited by 52

Modern therapeutic approaches to liver-related disorders

Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 51

Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators

Bustad, H. J., Kallio, J. P., Vorland, M., Fiorentino, V., Sandberg, S., Schmitt, C., Aarsand, A. K., & Martı́nez, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020675 · Cited by 49

Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases

Moosavi, S. G., Rahiman, N., Jaafari, M. R., & Arabi, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113641 · Cited by 54

Optimization of 5′ Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury

Sultana, N., Hadas, Y., Sharkar, M. T. K., Kaur, K., Magadum, A., Kurian, A. A., Hossain, N., Alburquerque, B., Ahmed, S. M. M., Chepurko, E., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.019 · Cited by 45

Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia

Attarwala, H. Z., Lumley, M., Liang, M., Ivaturi, V. D., & Senn, J. J. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0036 · Cited by 44

Update on the Porphyrias

Dickey, A. K., Leaf, R. K., & Balwani, M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-123602 · Cited by 51

Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics

Lee, Y., Jeong, M., Lee, G., Park, J., Jung, H., Im, S., & Lee, H. (2024) · Biomaterials Research · doi:10.34133/bmr.0017 · Cited by 51

Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications

Eftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 46

Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art

Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 45

Current and Future Treatments for Classic Galactosemia

Delnoy, B., Coelho, A. I., & Rubio‐Gozalbo, M. E. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020075 · Cited by 42

Delivery of synthetic mRNAs for tissue regeneration

Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42

Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice

Bartesaghi, S., Wallenius, K., Hovdal, D., Liljeblad, M., Wallin, S., Dekker, N., Barlind, L., Davies, N. M., Seeliger, F., Winzell, M. S., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.010 · Cited by 40

mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria

Gurung, S., Timmermand, O. V., Perocheau, D. P. B., Gil-Martínez, A. L., Minnion, M., Touramanidou, L., Fang, S., Messina, M., Khalil, Y., Śpiewak, J., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh1334 · Cited by 39

mRNA and gene editing: Late breaking therapies in liver diseases

Zabaleta, N., Torella, L., Weber, N. D., & González‐Aseguinolaza, G. (2022) · Hepatology · doi:10.1002/hep.32441 · Cited by 39

Lipid Nanoparticle-Mediated Delivery of mRNA Into the Mouse and Human Retina and Other Ocular Tissues

Chambers, C., Soo, G. L., Engel, A. L., Glass, I. A., Frassetto, A., Martini, P. G. V., & Cherry, T. J. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.7.7 · Cited by 36

Current and innovative emerging therapies for porphyrias with hepatic involvement

Fontanellas, A., Avila, M. A., Anderson, K. E., & Deybach, J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.003 · Cited by 36

Genetic-Based Approaches to Inherited Metabolic Liver Diseases

Zabaleta, N., Hommel, M., Salas, D., & González‐Aseguinolaza, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.140 · Cited by 35

Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?

Petrides, P. E., Klein, M., Schuhmann, E., Torkler, H., Molitor, B., Loehr, C., Obermeier, Z., & Beykirch, M. K. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04547-3 · Cited by 35

State-of-the-Art Review on Inhalable Lipid and Polymer Nanocarriers: Design and Development Perspectives

Costabile, G., Conte, G., Brusco, S., Savadi, P., Miro, A., Quaglia, F., d’Angelo, I., & Ungaro, F. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030347 · Cited by 37

Therapeutic strategies for acute intermittent porphyria

Zhao, L., Wang, X., Zhang, X., Liu, X., Ma, N., Zhang, Y., & Zhang, S. (2020) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2020.03089 · Cited by 36

mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends

Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 34

mRNA-based modalities for infectious disease management

Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35

Gene therapy for inherited metabolic diseases

Yılmaz, B. Ş., Gurung, S., Perocheau, D. P. B., Counsell, J. R., & Baruteau, J. (2020) · PubMed Central · doi:10.34763/jmotherandchild.20202402si.2004.000009 · Cited by 31

Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III

Jauze, L., Monteillet, L., Mithieux, G., Rajas, F., & Ronzitti, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.102 · Cited by 34

Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders

Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 33

Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle

Skerritt, J. H. (2025) · Vaccines · doi:10.3390/vaccines13050473 · Cited by 31

RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria

Sardh, E., & Harper, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13443 · Cited by 28

mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment

Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30

Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency

Khoja, S., Liu, X.-B., Truong, B., Nitzahn, M., Lambert, J., Eliav, A., Nasser, E., Randolph, E., Burke, K. E., White, R. A., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.012 · Cited by 26

The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review

Halma, M. T. J., Rose, J., Jenks, A., & Lawrie, T. A. (2023) · J — Multidisciplinary Scientific Journal · doi:10.3390/j6020017 · Cited by 25

The design, manufacture and LNP formulation of mRNA for research use

Leighton, L. J., Chaudhary, N., Tompkins, H. E., Kulkarni, A., Carrodus, N. L., Budzinska, M. A., Das, S. L., Cheetham, S. W., & Mercer, T. R. (2025) · Nature Protocols · doi:10.1038/s41596-025-01174-4 · Cited by 24

Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors

Gardin, A., & Ronzitti, G. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00227-0 · Cited by 22

RNA-based therapies in liver metabolic diseases

Fontanellas, A., Berraondo, P., Urigo, F., Jericó, D., Martini, P. G. V., Pastor, F., & Avila, M. A. (2025) · Gut · doi:10.1136/gutjnl-2023-331742 · Cited by 31

Givosiran for the treatment of acute hepatic porphyria

Ricci, A., & Ventura, P. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2075848 · Cited by 24

mRNA delivery technologies: Toward clinical translation

Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23

mRNA-Based Approaches to Treating Liver Diseases

Cacicedo, M. L., Limeres, M. J., & Gehring, S. (2022) · Cells · doi:10.3390/cells11203328 · Cited by 23

Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1

Kukreja, A., Lasaro, M. A., Cobaugh, C., Forbes, C. D., Tang, J., Gao, X., Martín-Higueras, C., Pey, A. L., SALIDO, E. C., Sobolov, S. B., et al. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0740 · Cited by 21

Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives

Marcacci, M., Ricci, A., Cuoghi, C., Marchini, S., Pietrangelo, A., & Ventura, P. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02314-9 · Cited by 24

High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach

Solares, I., Izquierdo‐Sánchez, L., Morales‐Conejo, M., Jericó, D., Castelbón, F. J., Córdoba, K. M., Sampedro, A., Lumbreras, C., Moreno-Aliaga, M. J., de Salamanca, R. E., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030255 · Cited by 21

The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA

Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 23

Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution

Longo, M., Paolini, E., Meroni, M., & Dongiovanni, P. (2022) · Biomedicines · doi:10.3390/biomedicines10030648 · Cited by 21

Overcoming the limitations of cytokines to improve cancer therapy

Trani, C. A. D., Cirella, A., Arrizabalaga, L., Fernández-Sendin, M., Bella, Á., Aranda, F., Melero, I., & Berraondo, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.05.002 · Cited by 22

Acute Intermittent Porphyria’s Symptoms and Management: A Narrative Review

Kizilaslan, E. Z., Ghadge, N. M., Martínez, A., Bass, M., Winayak, R., Mathew, M., Amin, R., Khan, M. K., & Kizilbash, N. (2023) · Cureus · doi:10.7759/cureus.36058 · Cited by 20

RNA nanomedicine in liver diseases

Bakrania, A. K., Mo, Y., Zheng, G., & Bhat, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000606 · Cited by 21

Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression

Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18

Novel treatment options for acute hepatic porphyrias

Wang, B. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000734 · Cited by 19

mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

Jericó, D., Córdoba, K. M., Jiang, L., Schmitt, C., Morán, M., Sampedro, A., Alegre, M., Collantes, M., Santamaría, E., Alegre, E., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.010 · Cited by 19

Heme (dys)homeostasis and liver disease

Duarte, T. L., Viveiros, N., Godinho, C., & Duarte, D. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1436897 · Cited by 18

Emerging mRNA Technology for Liver Disease Therapy

Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c02987 · Cited by 20

Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma

Zhang, Y., Rabinovsky, R., Deforzh, E., Kobayashi, A., Kuzkina, A., Varghese, J. F., Rai, D., Korecka, J. A., Khurana, V., Murugaiyan, G., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf162 · Cited by 18

RNA interference therapy in acute hepatic porphyrias

Yasuda, M., Keel, S., & Balwani, M. (2023) · Blood · doi:10.1182/blood.2022018662 · Cited by 18

Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies

Yasuda, M., & Desnick, R. J. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.01.007 · Cited by 17

Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

Córdoba, K. M., Jericó, D., Jiang, L., Collantes, M., Alegre, M., García-Ruiz, L., Manzanilla, O., Sampedro, A., Herranz, J. M., Insausti, I., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332619 · Cited by 10

Disease pharmacokinetic–pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA ‐based therapies

Parra-Guillen, Z. P., Fontanellas, A., Jiang, L., Jericó, D., Martini, P. G. V., Vera‐Yunca, D., Hard, M., Guey, L. T., & Trocóniz, I. F. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15040 · Cited by 14

Enzyme replacement therapy for acute intermittent porphyria and mRNA-based rescue in a new non-human primate model developed by long-term hepatic expression of iRNA

Córdoba, K. M. (2023) · doi:10.15581/10171/67871

Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment

Jericó, D., Córdoba, K. M., Sampedro, A., Jiang, L., Joucla, G., Cabanne, C., Lanciego, J. L., Martini, P. G. V., Berraondo, P., Avila, M. A., et al. (2022) · Life · doi:10.3390/life12111858 · Cited by 16

mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

Jericó, D., Córdoba, K. M., Jiang, L., Schmitt, C., Morán, M., Sampedro, A., Alegre, M., Collantes, M., Santamaría, E., Alegre, E., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.010 · Cited by 19